Lucy Scientific Discovery Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucy Scientific Discovery, Inc. is an early-stage company, which engages in the manufacture of psychotropics contracts. It focuses on the research, development, and manufacture of psychotropics-based medicines. Its products include raw materials, crude extracts, targeted formulations, white and private label products, and single molecule fractions. The company was founded on February 17, 2017 and is headquartered in Victoria, Canada.

VICTORIA, British Columbia and VANCOUVER, British Columbia, March 17, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) [NASDAQ:LSDI], an early-stage psychedelics manufacturing company, announced today that it has partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies.

Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities

VICTORIA, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or the “Company”) [NASDAQ:LSDI], an early-stage manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for traditionally stigmatized drugs including psychedelics announced today that it has agreed to its first commercial sale to the prestigious Hadassah BrainLabs - Center for Psychedelics Research, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.

Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs

LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, a Los Angeles based international investment bank and securities firm announced today the closing of an initial public offering for Lucy Scientific Discovery Inc., an early-stage psychotropics contract manufacturing company focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry.

WestPark Capital Announces Closing of $7.5 Million IPO for Lucy Scientific Discovery Inc. (NASDAQ:LSDI)

VICTORIA, British Columbia, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or the “Company”) [NASDAQ:LSDI], an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychedelics-based medicines industry, announced today that Chris McElvany, the Chief Executive Officer of Lucy, Richard Nanula, the Executive Chairman of Lucy, and other members of the Company's board of directors and leadership team will ring the Nasdaq Closing Bell today.

Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO

VICTORIA, British Columbia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. Nasdaq: LSDI, an early-stage psychotropics contract manufacturing company focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry (the “Company” or “Lucy”), today announced the closing of its previously announced initial public offering of 1,875,000 common shares at a public offering price of $4.00 per share, for gross proceeds of approximately $7.5 million before deducting offering expenses. Lucy's common shares are listed on the Nasdaq Capital Market under the ticker symbols “LSDI”, and commenced trading on February 9, 2023.

Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering

VICTORIA, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) --  Lucy Scientific Discovery Inc. ( “the Company”), an early-stage psychotropics contract manufacturing company focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry, today announced the pricing of its initial public offering of 1,875,000 common shares at a public offering price of $4.00 per share, for gross proceeds of approximately $7.5 million before deducting offering expenses. In addition, the Company has granted the Underwriters a 45 day over-allotment option to purchase an additional 15% or 281,250 shares.

Lucy Scientific Discovery Inc. NASDAQ:LSDI Announces Pricing of $7.5 Million IPO

Lucy Scientific Discovery has filed proposed terms for an $8 million U.S. IPO. The firm seeks to become a contract manufacturer for the regulated medicinal psychotropics industry in Canada and potentially the U.S.

IPO Update: Lucy Scientific Discovery Finalizes U.S. IPO Effort

News for Lucy Scientific Discovery Inc Stock (LSDI)